Human medicines European public assessment report (EPAR): Andembry, garadacimab, Date of authorisation: 10/02/2025, Revision: 3, Status: Authorised
Agenda - PDCO agenda of the 10-13 November 2026 meeting
Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 17, Status: Authorised
Agenda - HMA / EMA multistakeholder AI and Data forum: Build trustworthy AI on strong data foundations
Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, Date of authorisation: 21/09/2018, Revision: 29, Status: Authorised
Orphan designation: talquetamab Treatment of multiple myeloma, 20/08/2021 Withdrawn
Human medicines European public assessment report (EPAR): Talvey, talquetamab, Date of authorisation: 21/08/2023, Revision: 8, Status: Authorised
Biostatistics Operational Expert Group
Modelling and Simulation Operational Expert Group
Biologics Working Party Plasma Master File Quality Operational Expert Group (PMF OEG)